KATHLEEN TATE: Open Payments
NPI 1922614171 · FLOWOOD, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$836 in 27 payments from 13 companies in 2025. Trend: 2023 $166 · 2024 $1,278 · 2025 $836
Food & beverage: $836
| Company | Payments | Amount |
|---|---|---|
| Phathom Pharmaceuticals, Inc. | 2 | $144 |
| Janssen Scientific Affairs, LLC | 1 | $132 |
| Ardelyx, Inc. | 3 | $121 |
| Janssen Biotech, Inc. | 6 | $108 |
| Novo Nordisk Inc | 2 | $93 |
| ABBVIE INC. | 3 | $59 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $39 |
| Ferring Pharmaceuticals Inc. | 2 | $31 |
| Celltrion USA Inc. | 2 | $29 |
| Aimmune Therapeutics, Inc. | 1 | $22 |
Products named: TREMFYA, VOQUEZNA, IBSRELA, Wegovy, ENTYVIO, SKYRIZI, REBYOTA, VEGZELMA.
Industry payments across MS — which companies pay providers there.
